Skip Navigation


JAC Advance Access originally published online on September 14, 2007
Journal of Antimicrobial Chemotherapy 2007 60(5):999-1003; doi:10.1093/jac/dkm346
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Supplementary Data
Right arrow All Versions of this Article:
60/5/999    most recent
dkm346v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Silley, P.
Right arrow Articles by Pridmore, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Silley, P.
Right arrow Articles by Pridmore, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Comparative activity of pradofloxacin against anaerobic bacteria isolated from dogs and cats

Peter Silley1,2,*, Bernd Stephan3, Heinrich A. Greife3 and Andrew Pridmore4

1 MB Consult Limited, Lymington, SO41 3TQ, UK; 2 Department of Biomedical Sciences, University of Bradford, Bradford, UK; 3 Bayer HealthCare AG, Leverkusen, D-51368, Germany; 4 Don Whitley Scientific Ltd, Shipley, West Yorkshire, BD17 7SE, UK

Received 10 July 2007; returned 25 July 2007; revised 9 August 2007; accepted 10 August 2007

* Corresponding author. Tel: +44-1590-678700; Fax: +44-1590-678751; E-mail: p-s{at}mbconsult.co.uk

Objectives: To compare the intrinsic activity of pradofloxacin, a new fluoroquinolone developed for use in veterinary medicine, with other fluoroquinolones, against anaerobic bacteria isolated from dogs and cats.

Methods: One hundred and forty-one anaerobes were isolated from dogs and cats and comparative MICs of pradofloxacin, marbofloxacin, enrofloxacin, difloxacin and ibafloxacin were determined according to standardized agar dilution methodology.

Results: Pradofloxacin exerted the greatest antibacterial activity followed by marbofloxacin, enrofloxacin, difloxacin and ibafloxacin. Based on the distinctly lower MIC50, MIC90 and mode MIC values, pradofloxacin exhibited a higher in vitro activity than any of the comparator fluoroquinolones.

Conclusions: Pradofloxacin, a novel third-generation fluoroquinolone, has broad-spectrum anti-anaerobe activity and offers utility as single-drug therapy for mixed aerobic/anaerobic infections.

Keywords: fluoroquinolones , anaerobes , companion animals


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
B. Stephan, H. A. Greife, A. Pridmore, and P. Silley
Activity of Pradofloxacin against Porphyromonas and Prevotella spp. Implicated in Periodontal Disease in Dogs: Susceptibility Test Data from a European Multicenter Study
Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2149 - 2155.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.